Oxford's Ebola vaccine candidate has entered Phase 1 clinical trials for safety evaluation. The ChAdOx1 BDBV vaccine uses a platform similar to the Covid-19 vaccine. Serum Institute of India manufactured approximately 620,000 doses for potential future use. This initiative builds on a strategic partnership with CEPI and the University of Oxford. Late-stage trials will follow if Phase 1 results prove successful.

Scientists from the University of Oxford will begin injecting 50 adults in the UK with Ebola 'within weeks' in a bid to build immunity against the deadly virus.

Oxford University scientists have rapidly created and launched a UK trial of Ebola jab using same technology as its AstraZeneca vaccine against Covid-19

Estudo avaliará segurança e resposta imunológica em 50 adultos saudáveis entre 18 e 55 anos

Oxford begins first human trial of vaccine targeting Bundibugyo Ebola strain

Oxford Vaccine Group initiates the first Phase I trial for Bundibugyo ebolavirus vaccine with support from India's Serum Institute.